Overview

Prasugrel/Clopidogrel Maintenance Dose Washout Study

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to describe the cumulative proportion of participants who return to baseline platelet P2Y12 receptor function over time (up to 12 days post last maintenance dose) following discontinuation of prasugrel 10 mg daily x 7 days assessed by Accumetrics VerifyNow P2Y12 reaction units (PRU) and described by Kaplan Meier curves. The primary analysis is descriptive and is intended to provide information relating to the return of baseline platelet function following discontinuation of maintenance therapy with either prasugrel or clopidogrel.
Phase:
Phase 4
Details
Lead Sponsor:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.
Treatments:
Clopidogrel
Prasugrel Hydrochloride
Ticlopidine